Does adaptive radiotherapy for head and neck cancer favorably impact dosimetric, clinical, and toxicity outcomes?: A review.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
28 Jun 2024
28 Jun 2024
Historique:
medline:
28
6
2024
pubmed:
28
6
2024
entrez:
28
6
2024
Statut:
ppublish
Résumé
The current review aims to summarize the international experience of the impact of adaptive radiotherapy on dosimetry and clinical and toxicity outcomes. Additionally, it might trigger Radiation Oncologists to use ART and evaluate whether ART improves target volume coverage and/or normal tissue sparing and, consequently, therapeutic results. We conducted an electronic literature search of PubMed/MEDLINE and ScienceDirect from January 2007 to January 2023. The search adhered to the PRISMA guidelines and employed keywords such as ART, HNC, parotid gland, and target volume. Furthermore, we examined the reference lists for studies pertinent to the present review. This study included both retrospective and prospective studies that were considered for inclusion. ART replanning appears to be a sustainable strategy to minimize toxicity by improving normal tissue sparing. Furthermore, it can enhance target volume coverage by correctly determining the specific dose to be delivered to the tumor. In conclusion, this review confirmed that ART benefits dosimetric, clinical/therapeutic, and toxicity outcomes.
Identifiants
pubmed: 38941415
doi: 10.1097/MD.0000000000038529
pii: 00005792-202406280-00054
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e38529Informations de copyright
Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no funding and conflicts of interest to disclose.
Références
Joshi P, Dutta S, Chaturvedi P, Nair S. Head and neck cancers in developing countries. Rambam Maimonides Med J. 2014;5:e0009.
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.
Marur S, Forastiere A. Head and neck squamous cell carcinoma: update on epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2016;91:386–96.
Dhull K, Atri R, Dhankhar R, Chauhan A, Kaushal V. Major risk factors in head and neck cancer: a retrospective analysis of 12-year experiences. World J Oncol. 2018;9:80–4.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer Available at: http://globocan.iarc.fr. 2012.
Gregory T, Scott M, George E, Waun K. Head and neck cancer. In: James FH, Emil FN, Robert CB, Donald WK, Donald LM, Ralph RW, (eds). Cancer Medicine. Philadelphia: Lea and Febiger. 1993:1211–1274.
Cogliano V, Baan R, Straif K, et al. Preventable exposures associated with human cancers. J Natl Cancer Inst. 2011;103:1827–39.
Zygogianni A, Kyrgias G, Karakitsos P, et al. Oral squamous cell cancer: early detection and the role of alcohol and smoking. Head Neck Oncol. 2011;3.
Zygogianni A, Kyrgias G, Mystakidou K, et al. Potential role of the alcohol and smoking in the squamous-cell carcinoma of the head and neck: review of the current literature and new perspectives. Asian Pac J Cancer. 2011;12:339–44.
Machiels J, Rene Leemans C, Golusinski W, et al. Squamous cell carcinoma of the oral cavity, larynx, oropharynx, and hypopharynx: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2020;31:1462–75.
Vokes E. Head and neck cancer. In: Fauci AS, Braunwald E, Isselbacher KJ, et al., (eds). Harrison’s Principles of Internal Medicine. New York: McGraw Hill. 2005;16:503–506.
Pai S, Westra W. Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annu Rev Pathol. 2009;4:49–70.
Mali SB. Adaptive radiotherapy for head neck cancer. J Maxillofac Oral Surg. 2016;15:549–54.
Kouloulias V, Thalassinou S, Platoni K, et al. The treatment outcome and radiation-induced toxicity for patients with head and neck carcinoma in the IMRT era: a systematic review with dosimetric and clinical parameters. Biomed Res Int. 2013;401261.
Ackerstaff A, Rasch C, Balm A, et al. Five-year quality of life results of the randomized clinical phase III (RADPLAT) trial, comparing concomitant intra-arterial versus intravenous chemoradiotherapy in locally advanced head and neck cancer. Head Neck. 2012;34:974–80.
Langendijk J, Doornaert P, Verdonck-de Leeuw I, Leemans C, Aaronson N, Slotman B. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol. 2008;26:3770–6.
NCCN Clinical Practice Guidelines in Oncology. Head and neck cancers, version 2.2020. J Natl Compr Canc Netw. 2020;18:873–98.
Nutting C, Morden J, Harrington K, Urbano J, Bhide S, et al. Parotid-sparing intensity-modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicenter randomized controlled trial. Lancet Oncol. 2011;12:127–36.
Shang Q, Shen ZL, Ward MC, Joshi NP, Koyfman SA, Xia P. Evolution of treatment planning techniques in external-beam radiation therapy for head and neck cancer. Appl Radiat Oncol. 2015;4:18–25.
Connell P, Hellman S. Advances in radiotherapy and implications for the next century: a historical perspective. Cancer Res. 2009;69:383–92.
de Arruda F, Puri D, Zhung J, et al. Intensity-modulated radiation therapy for treating oropharyngeal carcinoma: memorial Sloan-Kettering cancer center. Int J Radiat Oncol Biol Phys. 2006;64:363–73.
Mallick I, Waldron J. Radiation therapy for head and neck cancer. Semin Oncol Nurs. 2009;25:193–202.
Ghosh A, Gupta S, Johny D, Bhosale V, Negi M. One study assessed the dosimetric impact of anatomical changes in the parotid glands and tumor volume during intensity-modulated radiotherapy using Simultaneous Integrated Boost (IMRT-SIB) for head and neck squamous cell cancers. Cancer Med. 2021;10:5175–90.
Burela N, Soni T, Patni N, Natarajan T. Adaptive intensity-modulated radiotherapy in head and neck cancer: a volumetric and dosimetric study. J Cancer Res Ther. 2019;15:533–8.
Lee C, Langen K, Lu W, et al. Assessment of parotid gland dose changes during radiotherapy for head and neck cancer using daily megavoltage computed tomography and deformable image registration. Int J Radiat Oncol Biol Phys. 2008;71:1563–71.
Thomson D, Beasley W, Garcez K, et al. Relative plan robustness of step-and-shoot vs. rotational intensity-modulated radiotherapy on repeat computed tomography simulation for weight loss in head and neck cancer. Med Dosim. 2016;41:154–8.
Buciuman N, Marcu L. Adaptive radiotherapy in head and neck cancer using volumetric modulated arc therapy. Am J Pers Med. 2022;12:668.
Nicosia L, Sicignano G, Rigo M, et al. Daily dosimetric variation between image-guided volumetric modulated arc radiotherapy and MR-guided daily adaptive radiotherapy for stereotactic body radiotherapy in prostate cancer. Acta Oncol. 2021;60:215–21.
Barker J, Garden A, Ang K, et al. Quantifying volumetric and geometric changes occurring during fractionated radiotherapy for head and neck cancer using an integrated CT/linear accelerator system. Int J Radiat Oncol Biol Phys. 2004;59:960–70.
Abdelhafiz N, Mahmoud D, Gad M, Essa H, Morsy A. Effect of definitive hypofractionated radiotherapy concurrent with weekly cisplatin treatment on locally advanced squamous cell carcinoma of the head and neck. J Med Life. 2023;16:743–50.
Baujat B, Borhis J, Blanchard P, et al. Hyperfractionated or accelerated radiotherapy for head and neck cancer. Cochrane Database Syst Rev. 2010;2010:CD002026.
Lacas B, Bourhis J, Overgaard J, et al. MARCH Collaborative Group. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol. 2017;18:1221–37.
Bourhis J, Overgaard J, Audry H, et al. Meta-Analysis of Radiotherapy in Carcinomas of Head and neck (MARCH) Collaborative Group. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006;368:843–54.
Bertholet J, Anastasi G, Noble D, et al. Patterns of practice for adaptive and real-time radiation therapy (POP-ART RT): part II offline and online plan adaptation for interfractional changes. Radiother Oncol. 2020;153:88–96.
Fu K, Pajak T, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48:7–16.
Yeh SA. Radiotherapy for head and neck cancer. Semin Plast Surg. 2010;24:127–36.
Aly F, Miller A, Jameson M, et al. A prospective study of weekly intensity modulated radiation therapy plan adaptation for head and neck cancer: improved target coverage and organ at risk sparing. Australas Phys Eng Sci Med. 2019;42:43–51.
Bhandari V, Patel P, Gurjar O, Lal Gupta K. Impact of repeat computerized tomography replan in the radiation therapy of head and neck cancers. J Med Phys. 2014;39:164–8.
Mahmoud O, Reis I, Samuels M, et al. Prospective pilot study comparing the need for adaptive radiotherapy in unresected bulky disease and postoperative patients with head and neck cancer. Technol Cancer Res Treat. 2017;16:1014–21.
Glide-Hurst C, Lee P, Yock A, et al. Adaptive radiation therapy (ART) strategies and technical considerations: a state of the ART review from NRG oncology. Int J Radiat Oncol Biol Phys. 2021;109:1054–75.
Heukelom J, Fuller C. Head and neck cancer Adaptive Radiation Therapy (ART): conceptual considerations for the informed clinician. Semin Radiat Oncol. 2019;29:258–73.
Alfouzan AF. Radiation therapy in head and neck cancer. Saudi Med J. 2021;42:247–54.
Figen M, Oksuz D, Duman E, et al. Radiotherapy for head and neck cancer: evaluation of triggered adaptive replanning in routine practice. Front Oncol. 2020;10:579917.
Nasser N, Yang G, Koo J, et al. Head and neck treatment planning strategy for a CBCT-guided ring-gantry online adaptive radiotherapy system. J Appl Clin Med Phys. 2023:e14134.
Schwartz DL, Garden AS, Thomas J, et al. Adaptive radiotherapy for head-and-neck cancer: initial clinical outcomes from a prospective trial. Int J Radiat Oncol Biol Phys. 2012;83:986–93.
Bobić M, Lalonde A, Nesteruk K, et al. Large anatomical changes in head and neck cancers: dosimetric comparison of online and offline adaptive proton therapy. Clin Transl Radiat Oncol. 2023;40:100625.
Surucu M, Shah K, Roeske J, Choi M, Small W, Emami B. Adaptive radiotherapy for head and neck cancer. Technol Cancer Res Treat. 2017;16:218–23.
Capelle L, Mackenzie M, Field C, Parliament M, Ghosh S, Scrimger R. Adaptive radiotherapy using helical tomotherapy for head and neck cancer in definitive and postoperative settings: initial results. Clin Oncol (R Coll Radiol). 2012;24:208–15.
Lu J, Ma Y, Chen J, et al. Assessment of anatomical and dosimetric changes using a deformable registration method during intensity-modulated radiotherapy for nasopharyngeal carcinoma. J Radiat Res. 2014;55:97–104.
Olteanu L, Berwoutz D, Madani I, et al. Comparative dosimetry of three-phase adaptive and non-adaptive dose-painting IMRT for head and neck cancers. Radiother Oncol. 2014;111:348–53.
Reali A, Anglesio S, Mortellaro G, et al. Volumetric and positional changes in planning target volumes and organs at risk using computed tomography imaging during intensity-modulated radiation therapy for head–neck cancer: an ‘‘old’’ adaptive radiation therapy approach. La Radiologia Medica. 2014;119:714–20.
Castelli J, Simon A, Louvel G, et al. Impact of head and neck cancer adaptive radiotherapy to spare the parotid glands and decrease the risk of xerostomia. Radiat Oncol. 2015;10:6.
Zhang P, Simon A, Rigaud B, Castelli J, Ospina Arango J, et al. Optimal adaptive IMRT strategy to spare the parotid glands in oropharyngeal cancer. Radiother Oncol. 2016;120:41–7.
van Kranen S, Hamming-Vrieze O, Wolf A, Damen E, van Herk M, Sonke J-J. Head and neck margin reduction with adaptive radiation therapy: treatment plan robustness against anatomical changes. Int J Radiat Oncol Biol Phys. 2016;96:653–60.
Dewan A, Sharma S, Dewan A, et al. Impact of adaptive radiotherapy on locally advanced head and neck cancer - a dosimetric and volumetric study. Asian Pac J Cancer Prev. 2016;17:985–92.
Deng S, Liu X, Lu H, Huang H, Shu L, et al. Three-phase adaptive radiation therapy for patients with nasopharyngeal carcinoma undergoing intensity-modulated radiation therapy: dosimetric analysis. Technol Cancer Res Treat. 2017;16:910–16.
Castelli J, Simon A, Laford C, et al. Adaptive radiotherapy for head and neck cancer. Acta Oncol. 2018;57:1284–92.
Mnejja W, Daoud H, Fourati N, et al. Dosimetric impact on changes in target volume during intensity-modulated radiotherapy for nasopharyngeal carcinoma. Rep Pract Oncol Radiother. 2020;25:41–5.
Hay L, Paterson C, McLoone P, Miguel-Chumacero E, Valentine R, et al. Dose analysis using CBCT and synthetic CT during head and neck radiotherapy: a single-center feasibility study. Tech Innov Patient Support Radiat Oncol. 2020;23:21–9.
Avkshtol V, Meng B, Shen C, Choi B, Okoroafor C, et al. Early experience of online adaptive radiation therapy for definitive radiation of head and neck cancer patients. Adv Radiat Oncol. 2023;8:101256.
Zhao L, Wan Q, Zhou Y, Deng X, et al. Role of replanning in fractionated intensity-modulated radiotherapy for nasopharyngeal carcinoma. Radiother Oncol. 2011;98:23–7.
Duma M, Kamper S, Schuster J, Winkler C, Geinitz H. Adaptive radiotherapy for soft tissue changes during helical tomotherapy for head and neck cancer. Strahlenther Onkol. 2012;188:243–7.
Jensen A, Nill S, Huber P, et al. Clinical concept of interfractional adaptive radiation therapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys. 2012;82:590–6.
Schwartz D, Garden A, Shah S, Chronowski G, Sejpal S, et al. Adaptive radiotherapy for head and neck cancer: dosimetric results from a prospective clinical trial. Radiother Oncol. 2013;106:80–4.
Yang H, Hu W, Wang W, Chen P, Ding W, Luo W. Replanning during intensity-modulated radiation therapy improved quality of life in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2013;85:e47–54.
Chen A, Daly M, Cui J, et al. Clinical outcomes of patients with head and neck cancer treated with intensity-modulated radiotherapy with and without adaptive replanning. Head Neck. 2014;36:1541–6.
Kataria T, Gupta D, Goyal S, et al. Clinical outcomes of adaptive radiotherapy for head and neck cancer. Br J Radiol. 2016;89:20160085.
El-Shahat M, Elshishtawy W, Al-Agamawi A. Evaluation of adaptive radiation therapy in treatment of locally advanced head and neck cancers. Am Al-Azhar Intern Med J. 2021;2:51–8.
Zhou X, Wang W, Zhou C, et al. Long-term outcomes of replanning during intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma: an updated and expanded retrospective analysis. Radiother Oncol. 2022;170:136–42.
Lee V, Schetllno G, Nisbet A. UK adaptive radiotherapy practices for head and neck cancer patients. BJR Open. 2020;2:20200051.